3-cyano-4,5-dihydroxybenzoic acid | 116314-77-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-cyano-4,5-dihydroxybenzoic acid
• 英文别名: 3,4-dihydroxy-5-cyanobenzoic acid
• CAS: 116314-77-3
• 化学式: C₈H₅NO₄
• 分子量: 179.132
• InChiKey: UVNLFDRZXWSAQU-UHFFFAOYSA-N

物化性质

• 沸点：
  448.1±45.0 °C(Predicted)
• 密度：
  1.70±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  102
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-cyano-4,5-dihydroxybenzoic acid 在 氯化亚砜 、 硫酸 作用下， 反应 2.33h， 生成 3-cyano-4,5-diacetoxybenzoyl chloride
  参考文献：
  名称：

  Pharmacokinetics of catechol cephalosporins. The effect of incorporating substituents into the catechol moiety on pharmacokinetics in a marmoset model

  摘要：

  Two series of cephalosporins A and B have been synthesized, bearing at C-3' catechols substituted with various electron withdrawing groups (Y) and differing links (X), and were evaluated for their in vitro antibacterial activity and their pharmacokinetics in marmosets. Compounds in series A, bearing an isobutyric oxime substituent, proved to be highly active against Gram-negative organisms and were especially noteworthy for showing long elimination phase (beta) half-lives in marmosets. It was established that introduction of electron withdrawing substituents greatly increased the beta-half-lives of compounds (5, X = NHCO, Y = H, t1/2 = 1.25 h, AUC = 27 mg/h per L; 11, X = NHCO, Y = 5-Cl, t1/2, = 4.5 h, AUC = 638 mg/h per L) and that the nature of the link also influenced t1/2, the highest values being obtained when X = NHCO and OCO. Acidities (pK(a) values) of the substituted catechols were measured, and relationships between the acidities and half-lives were evaluated. Thus it was established that the more acidic catechols gave the longest half-lives (12, X = NHCO, Y = 2,5-Cl2, t1/2 = 8.2 h, AUC = 461 mg/h per L). Further elaboration of the catechol to bicyclic systems maintained good pharmacokinetics when the pK(a) was sufficiently acidic.

  DOI：

  10.1021/jm00092a015
• 作为产物：
  描述：

  4-acetoxy-3-cyano-5-methoxybenzoic acid 在 三溴化磷 作用下， 以 (2S)-N-methyl-1-phenylpropan-2-amine hydrate 、 二氯甲烷 为溶剂， 以1.25 g (74%)的产率得到3-cyano-4,5-dihydroxybenzoic acid
  参考文献：
  名称：

  Pharmacologically active compounds, methods for the preparation thereof

  摘要：

  公式I的药理活性儿茶酚衍生物，其中R.sub.1和R.sub.2独立地包括氢、烷基、酰基、可选择地取代的芳酰基、较低的烷基磺酰基或烷基氨基甲酰基，或者一起形成较低的烷基亚甲基或环烷基亚甲基，X包括电负取代基，如卤素、硝基、氰基、较低的烷基磺酰基、磺胺基、醛基、羧基或三氟甲基，R.sub.3包括氢、卤素、羟基烷基、氨基、硝基、氰基、三

  公开号：

  US04963590A1

文献信息

• Antibiotic compounds
  申请人：Imperial Chemical Industries PLC

  公开号：US05447925A1

  公开（公告）日：1995-09-05

  The present invention provides a compound of the formula (I) ##STR1## wherein: R.sup.1 is 1-hydroxyethyl, 1-fluoroethyl or hydroxymethyl; R.sup.2 is hydrogen or C.sub.1-4 alkyl; n is zero or an integer 1 to 4; and P is a benzene ring substituted by groups R.sup.3 and R.sup.4 which are ortho with respect to one another wherein R.sup.3 and R.sup.4 are independently hydroxy or in vivo hydrolysable esters thereof; or P is a group of the formula (II) or (III) ##STR2## wherein M is oxygen or a group NR.sup.5 wherein R.sup.5 is hydrogen or C.sub.1-4 alkyl; ring P being optionally further substituted; or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof.

  本发明提供了一种式为(I)的化合物：##STR1## 其中：R.sup.1为1-羟乙基，1-氟乙基或羟甲基；R.sup.2为氢或C.sub.1-4烷基；n为零或整数1至4；P为苯环，被取代基R.sup.3和R.sup.4取代，R.sup.3和R.sup.4独立地为羟基或体内水解酯；或P为式(II)或(III)的基团：##STR2## 其中M为氧或基团NR.sup.5，其中R.sup.5为氢或C.sub.1-4烷基；环P可以选择进一步取代；或其药学上可接受的盐或体内水解酯。
• Pharmacologically active catechol derivatives
  申请人：Orion-yhtyma Oy

  公开号：US05446194A1

  公开（公告）日：1995-08-29

  A compound according to formula 1 ##STR1## wherein R.sub.1 and R.sub.2 independently represent hydrogen, carbamoyl which is substituted by an alkyl of 1 to 4 carbon atoms, alkylcarbonyl of 2 to 5 carbon atoms or phenyl carbonyl, X represents halogen nitro or cyano and R.sub.3 represents ##STR2## wherein R.sub.4 represents cyano or alkylcarbonyl of 2 to 5 carbon atoms and R.sub.5 represents carbamoyl which is unsubstituted or substituted with alkyl of 1 to 8 carbon atoms or which is substituted with hydroxyalkyl of 1 to 8 carbon atoms or pharmaceutically acceptable esters and salts thereof, and a pharmaceutically acceptable carrier therefor, as well as pharmaceutical compositions containing said compounds as COMT inhibitors.

  根据公式1，化合物的结构为：##STR1## 其中，R.sub.1和R.sub.2独立地表示氢、被1到4个碳原子的烷基取代的氨基甲酰基、2到5个碳原子的烷基羰基或苯基羰基，X表示卤素、硝基或氰基，而R.sub.3表示##STR2## 其中，R.sub.4表示氰基或2到5个碳原子的烷基羰基，R.sub.5表示未取代或被1到8个碳原子的烷基取代的氨基甲酰基，或被1到8个碳原子的羟基烷基取代的氨基甲酰基，或药学上可接受的酯和盐，以及其药学上可接受的载体。此外，还包括将该化合物作为COMT抑制剂的药物组合物。
• Method of treating Parkinson's Disease using pentanedione derivatives
  申请人：Orion-yhtyma Oy

  公开号：US05112861A1

  公开（公告）日：1992-05-12

  The invention concerns a method for the treatment of Parkinson's Disease. The method comprises administering a catechol-O-methyl-transferase inhibiting amount of a compound having the formula I ##STR1## wherein R.sub.1 and R.sub.2 independently represent hydrogen, alkylcarbamoyl of 2 to 5 carbon atoms or alkylcarbonyl of 2 to 5 carbon atoms, X represents nitro or cyano and R.sub.3 represents ##STR2## wherein R.sub.4 represents cyano or alkylcarbonyl of 2 to 5 carbon atoms and R.sub.5 represents cyano; alkylcarbonyl of 2 to 5 carbon atoms; or carbamoyl which is unsubstituted or substituted with alkyl of 1 to 8 carbon atoms, or hydroxyalkyl of 1 to 8 carbon atoms or pharmaceutically acceptable salts or esters thereof; and a sufficient amount of levodopa to treat Parkinson's Disease. A peripheral decarboxylase inhibitor such as carbidopa or benzerazide is also preferably administered.

  本发明涉及一种治疗帕金森病的方法。该方法包括向患者施用一种具有以下式子I的化合物，其中R1和R2独立地表示氢、2至5个碳原子的烷基氨基酰基或2至5个碳原子的烷基羰基，X表示硝基或氰基，R3表示下列式子：其中R4表示氰基或2至5个碳原子的烷基羰基，R5表示氰基、2至5个碳原子的烷基羰基、未取代或取代了1至8个碳原子的烷基、1至8个碳原子的羟基烷基的氨基甲酰基或其药学上可接受的盐或酯；以及足够的左旋多巴治疗帕金森病。此外，最好还要施用周围脱羧酶抑制剂，如卡比多巴或苯扎酰胺。
• Catechol derivatives, their physiologically acceptable salts, esters and their use in the treatment of tissue damage induced by lipid peroxidation
  申请人：ORION-YHTYMÄ OY

  公开号：EP0444899A2

  公开（公告）日：1991-09-04

  Known and new catechol derivatives may be used as medicinal antioxidants in the prevention or treatment of tissue damage induced by lipid peroxidation. The conditions and diseases which may be treated are for example heart diseases, rheumatoid arthritis, cancer, inflammatory diseases, a rejection reaction in organ transplants, ischemia, cancer and aging.

  已知的和新的儿茶酚衍生物可用作药用抗氧化剂，用于预防或治疗脂质过氧化引起的组织损伤。可治疗的病症和疾病包括心脏病、风湿性关节炎、癌症、炎症性疾病、器官移植中的排异反应、缺血、癌症和衰老等。
• ANTIBIOTIC CARBAPENEM DERIVATIVES
  申请人：ZENECA LIMITED

  公开号：EP0584085B1

  公开（公告）日：1998-09-09